Could a common sleep drug fight Alzheimer's? new trial aims to find out
NCT ID NCT06274528
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the sleep medication lemborexant (Dayvigo) can reduce levels of amyloid-beta and tau proteins in the blood and spinal fluid of older adults. These proteins are linked to Alzheimer's disease. The trial will enroll 201 healthy volunteers aged 65 and older, giving them either lemborexant or a placebo for six months to measure changes in these biomarkers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lemborexant (Dayvigo)
What this could lead to
If it works, this could point toward a way to slow Alzheimer's by improving sleep and reducing harmful brain proteins.
What could go wrong
This is an early phase 2 trial, so results are not yet proven. The drug may not lower biomarkers enough, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University in St. Louis, School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact